Neuroglial responses to CNS injury: Prospects for novel therapeutics

Trevor J. Kilpatrick, Helmut Butzkueven, Ben Emery, Mark Marriott, Bruce V. Taylor, Niall Tubridy

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Immune-mediated therapies can reduce the relapse rate in multiple sclerosis. However, there is no clear-cut evidence that any of these therapies substantially alter the long-term outcome for patients with progressive multiple sclerosis. The neurological disability that all too frequently accompanies multiple sclerosis is ultimately due to injury to target cells, principally oligodendroglia, within the nervous system. Recent data suggest that activation of leukemia inhibitory factor-receptor signaling is an important component of a neurobiological response that serves to limit the extent of immune-mediated injury. Therefore, inactivation of this pathway could provide a novel approach to the treatment of demyelinating disease.

Original languageEnglish (US)
Pages (from-to)869-878
Number of pages10
JournalExpert Review of Neurotherapeutics
Volume4
Issue number5
DOIs
StatePublished - Sep 1 2004

    Fingerprint

Keywords

  • Experimental autoimmune encephalomyelitis
  • Glia
  • Leukemia inhibitory factor
  • Magnetic resonance imaging
  • Multiple sclerosis
  • Oligodendrocyte
  • Optic neuritis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Kilpatrick, T. J., Butzkueven, H., Emery, B., Marriott, M., Taylor, B. V., & Tubridy, N. (2004). Neuroglial responses to CNS injury: Prospects for novel therapeutics. Expert Review of Neurotherapeutics, 4(5), 869-878. https://doi.org/10.1586/14737175.4.5.869